Nabriva is developing its lead product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. We are developing both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP) and intend to develop lefamulin for additional indications other than pneumonia.
Nabriva’s lead pleuromutilin product candidate, lefamulin, is being studied in two global, registrational Phase 3 clinical trials for the treatment of moderate to severe ... More >>
Nabriva Therapeutics Appoints Carrie Bourdow and Colin Broom to the Board
|DUBLIN, Ireland, June 26, 2017 – Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced the appointment of Carrie Bourdow, Senior Vice President and Chief Commercial Officer of Trevena, Inc., to the Company’s Board of Directors. With the completion of the Company’s redom... |
Nabriva Therapeutics plc Successfully Concludes Tender Offer for Outstanding Common Shares of Nabriva Therapeutics AG and Outstanding American Depositary Shares of Nabriva Therapeutics AG
|DUBLIN, Ireland, June 26, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (“Nabriva Therapeutics”) today announced that it has successfully concluded its previously announced tender offer related to the exchange of common shares (“Nabriva AG Common Shares”) of Nabriva Therapeutics AG (“Nabriva AG”) and American depositary shares of Nabriva AG (NASDAQ:NBRV) (“Nabriva AG ADSs”) for ordinary shares (“Nabriva Ireland Shares”) of Nabriva Therapeutics (the “Exchange Offer”).
The Exchange Offer... |
Nabriva Therapeutics Announces Webcast of Analyst & Investor Day on June 19, 2017
|VIENNA, Austria and KING OF PRUSSIA, Pa., June 05, 2017 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics, today announced that the Company will webcast its Analyst & Investor Day being held from 9:30 a.m. to 1:30 p.m. ET on June 19, 2017 in New York City.
Nabriva will provide an overv... |